|
R1
|
|
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study |
| |
|
|
|
R2
|
|
B-lymphocyte depletion with Rituximab induction and maintenance in CFS/ME. A multicenter, randomized, double blind, placebo-controlled study
|
| R3 |
|
6th Invest in ME International ME/CFS Conference 2011 The Way Forward for ME - A Case for Clinical Trials
|
| R4 |
|
Biomedical Research into ME Collaborative Meeting (BRMEC) Crowdsourcing for ME
|
| R5 |
|
8th Invest in ME International ME (ME/CFS) Conference 2013 Infection, Immunity and Myalgic Encephalomyelitis - Mainstreaming ME Research
|
| R6 |
|
Invest in ME proposal for an examination and research facility for ME
|
| R7 |
|
IiME Foundation project for examination and research facility for ME |
| |
|
R8
|
|
Bradley, A. S., Ford, B. and Bansal, A. S. (2013), Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clinical & Experimental Immunology, 172: 73–80. doi: 10.1111/cei.12043 http://onlinelibrary.wiley.com/doi/10.1111/cei.12043/abstract |